MIRM
Mirum·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Consensus Rating "Buy"
MACD Death Cross
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MIRM
Mirum Pharmaceuticals, Inc.
A biopharmaceutical company that develops novel therapies for cholestatic liveriseases
950 Tower Lane, Suite 1050, Foster City, California 94404
--
Mirum Pharmaceuticals, Inc., was incorporated in Delaware on May 2, 2018. The Company is a biopharmaceutical company focused on identifying, acquiring, developing and commercializing novel therapies for debilitating rare and orphan diseases.
Earnings Call
Q1/2025
Estimate EPS-0.27
Actual EPS-0.3
Estimate Revenue98.40M
Actual Revenue111.60M
Mirum Pharmaceuticals' Q1 2025 Earnings Call: Unpacking Contradictions on LIVMARLI Expansion, Volixibat Data, and Trial Enrollment Progress
May 07,2025 09:19
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.33
Actual EPS-0.12
Estimate Revenue108.10M
Actual Revenue127.78M
Mirum Pharmaceuticals Q2 2025: Unpacking Contradictions on Market Penetration, Sales Growth, and Clinical Strategy
Aug 06,2025 09:19
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.16
Actual EPS0.05
Estimate Revenue130.50M
Actual Revenue133.01M
Mirum Pharmaceuticals' Q3 2025: Contradictions Emerge on Dosing Instructions, LIVMARLI Sales, PFIC Growth, Volixibat Pricing, and Study Design Confidence
Nov 04,2025 06:50
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MIRM has released its 2025 Q3 earnings. EPS was reported at 0.05, versus the expected -0.16, beating expectations. The chart below visualizes how MIRM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MIRM has released its 2025 Q3 earnings report, with revenue of 133.01M, reflecting a YoY change of 47.17%, and net profit of 2.90M, showing a YoY change of 120.41%. The Sankey diagram below clearly presents MIRM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
